

Supplementary Materials: Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma

Anna Egorova, Sofia Shtykalova, Alexander Selutin, Natalia Shved, Marianna Maretina, Sergei Selkov, Vladislav Baranov and Anton Kiselev




Figure S1. Molecular structures of RGD1 (a), RGD0 (b), and R6 (c) peptides. The images were processed by PepDraw software (<http://pepdraw.com/>).




Figure S2. Transfection efficacy evaluation of RGD1-R6 and RGD0-R6-polyplexes formed with pCMV-lacZ plasmid in PANC-1 cells in presence of fetal bovine serum. * $p < 0.05$ compared to RGD0-polyplexes.




Figure S3. PANC-1 cell viability after HSV thymidine kinase expression and GCV treatment. Values are the mean \pm SD of the mean of triplicates. * $p < 0.05$, ** $p < 0.01$ compared to pCMV-lacZ-complexes.




Figure S4. Typical microphotographs in bright field after 96 h of GCV treatment. The PANC-1 cells were transfected with RGD1-R6/pCMV-lacZ polyplexes at N/P ratios of (a) 8/1, (c) 12/1; with RGD1-R6/pPTK1 complexes at (b) 8/1, (d) 12/1 charge ratio; with PEI/DNA complexes using (e) pCMV-lacZ and (f) pPTK1 plasmids; with (g) pCMV-lacZ and (h) pPTK1 plasmids only. Control wells contained (i) GCV treated intact cells and (j) untreated intact ones.




Figure S5. Apoptosis (a) and necrosis (b) of PANC-1 cells induced by GCV treatment after cell transfection with RGD1-R6/DNA or RGD1/DNA polyplexes formed with pPTK and pCMV-lacZ plasmids. Values are the mean \pm SEM of the mean of four independent experiments. * $p < 0.05$ compared to pCMV-lacZ-complexes.